Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II)

This publication has 40 references indexed in Scilit:

• TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis
  American Heart Journal, 1997
• Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction
  The American Journal of Cardiology, 1996
• Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy
  The American Journal of Cardiology, 1996
• LOW MOLECULAR WEIGHT HEPARIN(S)
  British Journal of Haematology, 1995
• Initial experience withhirudin andstreptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trial
  The American Journal of Cardiology, 1995
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
  Published by Elsevier ,1994
• Dynamic changes of the QRS complex in unstable angina pectoris
  International Journal of Cardiology, 1992
• Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study
  Journal of the American College of Cardiology, 1992
• Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy
  American Heart Journal, 1991
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
  The American Journal of Cardiology, 1990